Gilead Sciences

This study looks at whether switching to a combination of bictegravir and lenacapavir (two drugs) works as well as staying on a more complex HIV treatment regimen. About 689 adults with HIV-1 who have the virus under control will take part. The goal is to see if the simpler regim…

This study tests the long-term safety of a drug called seladelpar in people with primary biliary cholangitis (PBC), a chronic liver disease. About 340 adults who have already taken seladelpar in a previous study will continue taking it for up to several years. Researchers will mo…

This study tests a drug called sacituzumab govitecan in 80 Chinese patients with metastatic triple-negative breast cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors or slow the disease. This is a phase 2 trial, meaning i…

This study follows 170 people with chronic hepatitis D who are taking bulevirtide to see how the drug affects their liver health over time. Researchers will monitor for serious liver problems like liver failure, cancer, or need for transplant, as well as side effects. The goal is…

This phase 3 study tests whether the experimental drug sacituzumab govitecan helps people with advanced non-small cell lung cancer live longer than the standard chemotherapy docetaxel. The trial includes 603 adults whose cancer worsened after platinum-based chemo and immunotherap…

This study tests whether switching to a new two-drug combination pill (bictegravir/lenacapavir) is as safe and effective as staying on the standard three-drug pill (Biktarvy) for people with HIV-1 whose virus is already under control. About 577 participants who have been on Bikta…

This study tests a three-in-one pill (Bictegravir/Emtricitabine/Tenofovir Alafenamide) for HIV-1 in children and teens aged 2 to 17. The goal is to see how the body processes the drug, confirm the right dose, and check safety. Participants take the pill once daily, and researcher…

This early-phase study tests a new drug called GS-9716 (zamzetoclax) in about 145 people with advanced solid tumors that have not responded to other treatments. The drug is given alone or with other cancer therapies to find the safest dose and check for side effects. The goal is …

This study tests whether people with well-controlled HIV can switch from a daily pill (B/F/TAF) to a once-weekly pill (Islatravir/Lenacapavir) and keep the virus suppressed. About 600 adults who have had undetectable HIV for at least 6 months will take either the weekly or daily …

This study tests whether a once-weekly pill (islatravir + lenacapavir) can keep HIV under control in people whose virus is already suppressed by daily medication. About 142 adults with HIV-1 who have been on a stable daily regimen for at least 24 weeks will switch to the weekly p…

This phase 3 study tests whether a new combination of drugs (sacituzumab govitecan and pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that has a specific marker (PD-L1). About 443 participants who h…

This study compares a new drug, sacituzumab govitecan, to standard chemotherapy in people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least two prior chemotherapies. The goal is to see if the new drug can slow cancer growth or improve sur…

This study tests a new long-acting injectable drug, lenacapavir, in people with HIV that has become resistant to many current medications. The goal is to see if adding this drug to their existing treatment can lower the amount of virus in their blood. The study involves 72 adults…

This study tests whether a new combination of two drugs (zimberelimab and domvanalimab) plus chemotherapy helps people with advanced non-small cell lung cancer live longer compared to the current standard treatment (pembrolizumab plus chemotherapy). About 1021 adults with untreat…

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the disease is …

This study tests whether the drug sacituzumab govitecan can help people with endometrial cancer that has come back after chemotherapy and immunotherapy. About 640 participants will receive either the study drug or a standard treatment chosen by their doctor. The goal is to see if…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab and sometimes chemotherapy for people with advanced or metastatic non-small-cell lung cancer that has no targetable genetic changes. About 193 participants who have not had prior treatment for their …

This early-stage study tests the safety and tolerability of a new drug called GS-0272 in 55 adults with rheumatoid arthritis. Participants receive multiple doses of the drug or a placebo to see how the body handles it and whether it causes side effects. The goal is to gather init…

This study tests a drug called sacituzumab govitecan against standard chemotherapy in people with advanced triple-negative breast cancer that does not have a protein called PD-L1. The goal is to see if the new drug can delay cancer growth or improve survival. About 623 participan…

This study tests if people with HIV whose virus is already controlled can switch to a once-weekly pill (islatravir/lenacapavir) instead of their daily medication. About 600 adults will either switch to the weekly pill or stay on their current daily treatment. The main goal is to …

This study tests whether the drug sacituzumab govitecan can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer growing, compared to standard chemotherapy. About 654 participants who have already tried hormone therapy will receive…

This study tests whether a combination of two lab-made antibodies (teropavimab and zinlirvimab) plus the drug lenacapavir, given as injections every 6 months, can keep HIV under control in adults whose virus is already suppressed by daily pills. About 83 participants will either …

This early-stage study tests a new drug called GS-4528, given alone or with another cancer drug, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 182 people will take part.

This study tests if a new once-weekly pill (GS-1720 plus GS-4182) can keep HIV under control as well as the daily medication Biktarvy. About 675 adults with already-suppressed HIV will switch to the weekly pill or stay on Biktarvy. The goal is to see if the weekly option is safe …

This study tests a new drug called GS-1427 for people with moderate to severe ulcerative colitis, a chronic bowel disease. About 228 adults will receive either the drug or a placebo to see if it improves symptoms like bleeding and stool frequency after 12 weeks. The goal is to co…

This study tests whether the antiviral drug tenofovir can safely lower hepatitis B virus levels in children aged 2 to 12 with chronic infection. Participants receive either the drug or a placebo for 48 weeks. The goal is to see if the drug can control the virus and improve liver …

This study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or returned and cannot be cur…

This study tests the safety and proper dosing of three HIV drugs (atazanavir, darunavir, and emtricitabine/tenofovir alafenamide) in children from 4 weeks to under 18 years old who already have the virus under control. The goal is to find the right dose for different age and weig…

This study tests whether combining immunotherapy drugs can shrink tumors in people with advanced non-small cell lung cancer. About 400 adults with stage IV cancer will receive these combinations. The main goals are to see how many patients respond and to check for side effects.

This early-phase study tests a new drug called GS-9911, given alone or with an immunotherapy drug, in 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is a first step to see if the a…

This study tests a drug called sacituzumab govitecan in 227 people whose solid tumors have spread to other parts of the body. The goal is to see if the drug can shrink or control the cancer. Participants must have already tried standard treatments like chemotherapy or immunothera…

This study tested a long-acting shot called lenacapavir, given every 6 months, to prevent HIV infection. Over 3,200 participants (cisgender men, transgender women, transgender men, and gender nonbinary people) who were at risk of HIV took part. The results showed that lenacapavir…

This study tested two ways to prevent HIV in over 5,000 adolescent girls and young women at risk of infection. One group received a twice-yearly injection of lenacapavir, while another took a daily pill (emtricitabine/tenofovir alafenamide). The goal was to see how well each meth…

This study looks at a new HIV prevention option for cisgender women in the US: a shot given under the skin every 6 months, called lenacapavir. Researchers want to see how the drug behaves in the body, how safe it is, and if women find it acceptable compared to taking a daily pill…

This early-phase study tests the safety and how the body handles a single-dose HIV prevention drug (B/F/TAF) in 16 full-term newborns who were exposed to HIV at birth but are not infected. The goal is to see if the drug is safe and how it moves through the babies' bodies, helping…

This study tested a new daily pill (F/TAF) to see if it could prevent HIV infection better than the current standard pill (F/TDF). About 5,400 men and transgender women at high risk of HIV took part. The main goal was to compare how many people got HIV while taking each pill over…

This study aimed to test the safety and effectiveness of the drug obeldesivir in preventing filovirus diseases like Ebola after a known or suspected exposure. It was designed for people who had high-risk contact with the virus within the past 21 days. However, the study was withd…

This study looks at a new long-acting shot called lenacapavir, given every 6 months, to prevent HIV in people who inject drugs. About 181 participants in the US will receive either the shot or daily pills, and researchers will check how the drug moves through the body and if it i…

This study tests a new HIV prevention method: a shot called lenacapavir given only twice a year. It compares how well people stick with this shot versus taking a daily pill (Truvada). The study involves 268 people at higher risk of HIV, including men who have sex with men, transg…